MX2020002921A - Anticuerpos para claudin6 y métodos para tratar el cáncer. - Google Patents

Anticuerpos para claudin6 y métodos para tratar el cáncer.

Info

Publication number
MX2020002921A
MX2020002921A MX2020002921A MX2020002921A MX2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A
Authority
MX
Mexico
Prior art keywords
methods
antigen
claudin6
antibodies
treat cancer
Prior art date
Application number
MX2020002921A
Other languages
English (en)
Other versions
MX428953B (es
Inventor
Dylan Conklin
Dennis Slamon
Neil O''BRIEN
Mike Palazzolo
Euw Erika Von
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2020002921A publication Critical patent/MX2020002921A/es
Publication of MX428953B publication Critical patent/MX428953B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona proteínas de unión a antígeno que se unen a Claudin-6 (CLDN6). En varios aspectos, las proteínas de unión a antígeno se unen al bucle extracelular 2 (EL2) del dominio extracelular de CLDN6. Se proporcionan adicionalmente polipéptidos, ácidos nucleicos, vectores, células hospedantes y conjugados en la presente memoria. Se proporcionan, además, kits y composiciones farmacéuticas que comprenden dichas entidades. También se proporcionan métodos para producir una proteína de unión a antígeno y métodos para tratar a un sujeto que tiene cáncer.
MX2020002921A 2017-09-18 2018-09-18 Anticuerpos para claudin6 y métodos para tratar el cáncer MX428953B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Publications (2)

Publication Number Publication Date
MX2020002921A true MX2020002921A (es) 2020-09-28
MX428953B MX428953B (es) 2025-11-13

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002921A MX428953B (es) 2017-09-18 2018-09-18 Anticuerpos para claudin6 y métodos para tratar el cáncer
MX2025012685A MX2025012685A (es) 2017-09-18 2020-03-17 Anticuerpos para claudin6 y metodos para tratar el cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025012685A MX2025012685A (es) 2017-09-18 2020-03-17 Anticuerpos para claudin6 y metodos para tratar el cancer

Country Status (22)

Country Link
US (4) US20200291111A1 (es)
EP (2) EP3826667B1 (es)
JP (2) JP7599332B2 (es)
KR (2) KR102793719B1 (es)
CN (2) CN111565744B (es)
AU (2) AU2018334434B2 (es)
BR (1) BR112020005196A2 (es)
CA (1) CA3076207A1 (es)
CZ (1) CZ2021138A3 (es)
DK (1) DK3826667T3 (es)
ES (1) ES2986343T3 (es)
FI (1) FI3826667T3 (es)
GB (1) GB202103867D0 (es)
HU (1) HUE067603T2 (es)
IL (2) IL313238A (es)
MX (2) MX428953B (es)
NO (1) NO20210351A1 (es)
PL (1) PL3826667T3 (es)
PT (1) PT3826667T (es)
SG (1) SG11202002114RA (es)
SI (1) SI3826667T1 (es)
WO (1) WO2019056023A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
AU2023219174A1 (en) * 2022-02-09 2024-08-15 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
JPWO2025075127A1 (es) * 2023-10-04 2025-04-10
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
AU2025213885A1 (en) * 2024-02-01 2026-07-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cldn6 antibody, antibody-drug conjugate thereof, and medical use thereof
WO2026084392A1 (ko) * 2024-10-14 2026-04-23 에이비엘바이오 주식회사 항-클라우딘6 항체 및 이의 용도
KR102953072B1 (ko) * 2025-08-20 2026-04-16 주식회사 누리사이언스 난소 및 난자의 성숙 및/또는 발달을 위한 조성물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
AU2014346792A1 (en) * 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer

Also Published As

Publication number Publication date
MX2025012685A (es) 2025-11-03
SG11202002114RA (en) 2020-04-29
KR20250050137A (ko) 2025-04-14
CN111565744B (zh) 2024-12-31
IL273196B2 (en) 2024-11-01
JP7599332B2 (ja) 2024-12-13
IL313238A (en) 2024-07-01
AU2018334434A1 (en) 2020-04-02
MX428953B (es) 2025-11-13
IL273196A (en) 2020-04-30
CN118667021A (zh) 2024-09-20
US20250333501A1 (en) 2025-10-30
NO20210351A1 (en) 2021-03-18
EP3826667A2 (en) 2021-06-02
CA3076207A1 (en) 2019-03-21
EP4435009A3 (en) 2025-02-26
KR102793719B1 (ko) 2025-04-08
HUE067603T2 (hu) 2024-10-28
US20220372134A1 (en) 2022-11-24
ES2986343T3 (es) 2024-11-11
CN111565744A (zh) 2020-08-21
SI3826667T1 (sl) 2024-09-30
CZ2021138A3 (cs) 2021-09-15
KR20200070238A (ko) 2020-06-17
US20240400674A1 (en) 2024-12-05
BR112020005196A2 (pt) 2020-09-15
JP2024150445A (ja) 2024-10-23
AU2018334434B2 (en) 2025-01-23
PT3826667T (pt) 2024-08-02
JP2020536507A (ja) 2020-12-17
EP4435009A2 (en) 2024-09-25
EP3826667B1 (en) 2024-04-17
PL3826667T3 (pl) 2024-09-30
IL273196B1 (en) 2024-07-01
WO2019056023A2 (en) 2019-03-21
JP7869831B2 (ja) 2026-06-03
FI3826667T3 (fi) 2024-07-22
AU2025200467A1 (en) 2025-04-10
DK3826667T3 (da) 2024-07-22
WO2019056023A3 (en) 2019-05-16
GB202103867D0 (en) 2021-05-05
EP3826667A4 (en) 2022-07-27
US20200291111A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2018001566A (es) Construcciones de union a antigeno para moleculas diana.
MX2024010984A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
EA201992206A1 (ru) Моноклональное антитело к pd-l1
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1